FDA Calls on Patent Office to Fend Off Rising U.S. Drug Costs (1)

Sept. 10, 2021, 10:28 PMUpdated: Sept. 13, 2021, 1:52 PM

The Food and Drug Administration is asking the U.S. Patent and Trademark Office for a hand in curbing drug costs as part of President Joe Biden’s plan to promote competition within the pharmaceutical industry.

Patents have come center stage in a fight being waged in Congress, the administration, and industry over U.S. drug costs. Policy experts say major drug companies have erected patents around products in ways that make it more difficult for generics to enter the marketplace.

FDA Acting Commissioner Janet Woodcock on Friday urged the PTO to chime in on the debate, asking the agency whether it’s “considering ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.